Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GlaxoSmithKline has announced the commencement of phase III study of Benlysta (belimumab) in patients with ANCA (Anti-neutrophil Cytoplasmic Antibodies) positive vasculitis.
Subscribe to our email newsletter
The phase III study is a multi-centre, multi-national study evaluating belimumab.
Randomised, double-blind study is designed to asses efficacy and safety profile of belimumab as a combination therapy with azathioprine for the maintenance of remission of ANCA associated Vasculitis (Granulomatosis with Polyangiitis (Wegener’s) or microscopic polyangiitis).
Belimumab belongs to a drug class known as BLyS-specific inhibitors.
In 2011, FDA had approved the drug to treat adult patients receiving standard therapy for active, autoantibody-positive systemic lupus erythematosus.
The European Commission also approved Belimumab in 2011 as an add-on therapy for adults with active, autoantibody-positive SLE with a high degree of disease activity in spite of standard therapy.